UPDATE - The Oncology Institute of Hope & Innovation Adds Los Angeles Practices to Network
TOI has expanded its physician network by acquiring the practices of Dr. Ellsworth R. Grant and Dr. Leo E. Orr, adding to its team of over 80 clinicians. This acquisition will enhance TOI's ability to provide value-based oncology care to more than 1.5 million patients across its locations.
The new facility in Westlake offers advanced medical services similar to other TOI clinics, enhancing patient access to high-quality cancer care.
- Acquisition of two experienced physicians strengthens TOI's clinical team.
- Expansion of network enhances patient access to advanced cancer care.
- None.
TOI is excited to welcome additional physicians to its team of 80+ employed clinicians
LOS ANGELES, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The Oncology Institute for Hope and Innovation (TOI), one of the largest value-based community oncology groups in the United States, recently acquired the practices of Ellsworth R. Grant, MD, and Leo E. Orr, MD, expanding TOI’s network of more than 80 specially trained physicians and advanced practice providers.
“By joining with TOI, I can continue to provide personalized care to my patients while leveraging TOI’s outstanding medical resources,” Dr. Grant stated. Dr. Orr agreed, adding, “I am proud to join such a well-respected group of practitioners with a powerful reputation for cutting-edge care.”
The new Westlake facility will provide patients with the same advanced medical services and health care available to patients at all TOI locations.
The office is located at:
1245 Wilshire Blvd, Suite 801
Los Angeles, CA 90017
Call (213) 481-3948 for appointments.
Founded in 2007, TOI is one of the largest value-based oncology practices in the U.S., taking accountability for both the quality outcomes as well as the medical costs associated with a population of more than 1.5 million patients. They offer a diverse set of cutting-edge resources including:
- A leading clinical research program offering patients access to more than 130 clinical trials.
- Comprehensive dispensary services to offer convenience and savings to patients receiving oral chemotherapeutics.
- A care management program which helps patients navigate a complex health care system.
- A state-of-the-art website with educational resources, scheduling capabilities, and a convenient patient portal.
“We are excited to add Drs. Grant and Orr to TOI’s growing team of premier oncologists. Both physicians bring a wealth of medical knowledge and will provide outstanding care for our patients,” TOI COO Dr. Daniel Virnich remarked.
Advisors
Jefferies LLC acted as lead financial advisor and Guggenheim Securities, LLC acted as financial advisor to The Oncology Institute. Deutsche Bank Securities Inc. and UBS Investment Bank acted as financial advisors to DFP. Deutsche Bank Securities Inc., Jefferies LLC and UBS Investment Bank acted as capital markets advisors to DFP. Latham & Watkins LLP acted as legal advisor to The Oncology Institute, White & Case LLP and Polsinelli PC acted as legal advisors to DFP, and Katten Muchin Rosenman LLP acted as legal advisor to Deerfield. Deutsche Bank Securities Inc., Jefferies LLC, UBS Investment Bank and Guggenheim Securities, LLC, acted as placement agents on the PIPE and Sidley Austin LLP acted as legal counsel to the placement agents.
About The Oncology Institute
Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, the expectation that the Company’s common stock will begin trading on Nasdaq, and the anticipated benefits of the business combination. These statements are based on various assumptions and on the current expectations of DFP and The Oncology Institute and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DFP and The Oncology Institute. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect the combined company or the expected benefits of the business combination; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on the combined company’s business; those factors discussed in the documents of DFP or TOI filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DFP nor The Oncology Institute presently know or that DFP and The Oncology Institute currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DFP’s and The Oncology Institute’s expectations, plans or forecasts of future events and views as of the date of this press release. DFP and The Oncology Institute anticipate that subsequent events and developments will cause DFP’s and The Oncology Institute’s assessments to change. DFP and The Oncology Institute do not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing DFP’s and The Oncology Institute’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts
Media
The Oncology Institute
Julie Korinke
juliekorinke@theoncologyinstitute.com
(562) 735-3226 x 88806
Revive
Michael Petrone
mpetrone@reviveagency.com
(615) 760-4542
Investors
Solebury Trout
Maria Lycouris
mlycouris@soleburytrout.com
FAQ
What recent acquisition did TOI make?
How many clinicians does TOI now employ?
Where is the new TOI facility located?
What type of care does TOI provide?
What is the significance of TOI's expansion?
What is the stock symbol for The Oncology Institute?
